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Background: The majority of lesions resulting in pathological nipple discharge are 
benign. Conventional surgery is undirected and targeting the causative lesion by duct 
endoscopy may enable more accurate surgery with fewer complications.  
 
Methods: Patients requiring microdochectomy and/or major duct excision were 
randomized to duct endoscopy or no duct endoscopy before surgery. Primary 
endpoints were successful visualization of the pathological lesion in patients 
randomized to duct endoscopy, and a comparison of the causative pathology 
between the two groups. The secondary endpoint was to compare the specimen size 
between groups.  
 
Results: A total of 68 breasts were studied in 66 patients; there were 31 breasts in 
the duct endoscopy and 37 in the no-endoscopy group. Median age was 49 (range 
19–81) years.  Follow-up was 5.4 (i.q.r. 3.3–8.9) years in the duct endoscopy group 
and 5.7 (3.1–9.0) years in no-endoscopy group.  Duct endoscopy had a sensitivity of 
80 (95 per cent c.i. 52 to 96) per cent, specificity of 71 (44 to 90) per cent, positive 
predictive value of 71 (44 to 90) and negative predictive value of 80 (52 to 96) per 
cent in identifying any lesion. There was no difference in causative pathology 
between the groups. Median volume of the surgical resection specimen did not differ 
between groups. 
 
Conclusion: Diagnostic duct endoscopy is useful for identifying causative lesions of 
nipple discharge. Duct endoscopy did not influence the pathological yield of benign or 
malignant diagnoses nor surgical resection volumes. Registered as INTEND II in 
CancerHelp UK clinical trials database (https://www.cancerresearchuk.org/about-
cancer/find-a-clinical-trial/a-study-looking-at-changes-inside-the-breast-ducts-of-
women-who-have-nipple-discharge). 
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Introduction 
In 5–21 per cent of patients, breast cancer presents with nipple discharge as the 
primary symptom1–6. The majority of women with nipple discharge, however, have 
benign conditions. This underlines the importance of an accurate diagnosis of an 
uncommon early presentation of breast cancer while not overtreating the vast 
majority of women with benign disease. In the presence of nipple discharge, a higher 
risk of breast cancer is recognized when the patient is aged over 50 years with a 
palpable mass, or a defined abnormality is observed on imaging or in cytology of the 
nipple discharge fluid3–7. Blood-stained nipple discharge carries a higher risk of being 
associated with malignancy than discharge of any colour or serous/clear nipple 
discharge, with odds ratios of 2.27 (95 per cent c.i. 1.32 to 3.89) and 2.49 (1.25 to 
4.94) respectively8.  
The current diagnostic standard for nipple discharge is histology of the 
affected duct7,8. The cytology of nipple discharge has variable sensitivity (23–73 per 
cent) and limited specificity (59–76 per cent)6,9,10. The presence of red blood cells in 
nipple discharge, either on stick testing or cytology, is not a reliable marker for breast 
cancer6,7,11.  The sensitivity and specificity of mammography in identifying breast 
cancer in patients with pathological nipple discharge are 18–57 and 33–94 per cent, 
whereas those for ultrasound examination are 73– 83 and 18–29 per cent, 
respectively8,10. MRI is not currently recommended as a standard investigation for 
nipple discharge12. As a research tool, MRI in combination with ductal contrast has 
modest sensitivity (55 per cent), specificity (67 per cent), positive predictive value 
(PPV) (85 per cent) and negative predictive value (NPV) (31 per cent)13. 
These widely used imaging investigations do not necessarily help the surgeon 
to localize the pathological lesion within the ductal tree of the breast unless wire 
localization of a definitive lesion is feasible and undertaken before surgery. 
Ductography is used less often but has the advantage of highlighting the anatomy in 
three dimensions. This enables the surgeon to determine the surgical strategy in 
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terms of identifying the affected duct, the distance from the nipple surface and the 
identification of potential multiple lesions. Ductography also distinguishes duct 
ectasia from space-occupying lesions, allowing non-surgical intervention in patients 
with minimally symptomatic nipple discharge. Ductography has acceptable sensitivity 
but limited specificity (79 and 12 per cent respectively) in the identification of cancer8. 
Although ductography may enable direct visualization of the causative lesion, it does 
not allow real-time planning for surgical intervention. 
Developments in fibre-optic technology and the evolution of microendoscopic 
instruments have been revolutionary over the past two decades. Endoscopy allows 
direct visualization of the breast ducts, enabling distinction between normal and 
abnormal areas, and targeting of visible lesions that correlate with subsequent 
postoperative surgical pathology with a sensitivity of 71.2 per cent and specificity of 
49.4 per cent10. The most common recognizable lesions are duct ectasia and benign 
polyps. Raised flat lesions, erythema and stranding are often benign, but can also be 
associated with atypical ductal lesions. The efficiency of duct endoscopy in improving 
preoperative diagnosis is reported variably. A range of indications for endoscopy, 
non-uniform classification of recognizable abnormalities, different methods for 
localization of any visualized lesion for surgery and different surgical techniques for 
removal have been described. Despite these limitations, a meta-analysis14 of 20 
studies concluded that duct endoscopy provides an accurate means of identifying 
surgical pathology. Duct endoscopy has been proposed as a way of selecting which 
women with pathological nipple discharge require surgery15–17. The use of 
interventional duct endoscopy in resection of papillomas has been described18,19, but 
its efficacy and cost-effectiveness is controversial in the context of what is essentially 
a benign disease. 
Patients with single-duct persistent nipple discharge requiring surgery, but 
without any clinical mass or suspicious lesions on imaging, were included in this 
RCT. The hypothesis was that targeting a visualized causative lesion by duct 
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endoscopy before standard surgical excision would enable smaller resection 
volumes, resulting in improved aesthetic outcome and a lower risk of complications.  
The primary endpoints were to assess the rate of successful visualization of a 
pathological lesion before a standard microdochectomy or major duct excision; and 
to compare the causative pathology between the duct endoscopy and no-endoscopy 
groups.  The secondary endpoint to compare the volumes of the resection 
specimens. 
 
Methods 
The study was approved by the institutional Committee for Clinical Research 
(CCR2747) and registered in the CancerHelp UK clinical trials database 
(https://www.cancerresearchuk.org/about-cancer/find-a-clinical-trial/a-study-looking-
at-changes-inside-the-breast-ducts-of-women-who-have-nipple-discharge). Patients 
who met the inclusion criteria were invited to participate and informed consent was 
obtained. Women were randomized to undergo either diagnostic duct endoscopy or 
no endoscopy before admission to hospital. A random allocation sequence was 
computer-generated at the Institute of Cancer Research – Clinical Trials Statistics 
Unit randomization centre. Patients were allocate in a 1 : 1 ratio stratified by site 
using block sizes of four and six. 
All operations were performed as a day-case procedure by a single surgical 
team. Women randomized to duct endoscopy underwent the procedure immediately 
before the start of the planned open resection under the same general anaesthetic.  
A consistent duct endoscopy protocol was applied. Endoscopy was 
performed initially on the symptomatic discharging duct, systemically inspecting first-
order and subsequent branches, before proceeding to any identifiable additional fluid 
yielding ducts worthy of inspection. Findings at duct endoscopy were classified as: 
papilloma, duct ectasia, flat raised lesion, irregular raised plaque, stricture, erythema 
and stranding. Localization of any abnormality before surgical excision was achieved 
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using an expanding rhomboid guidewire passed down the working channel of the 
microendoscope. A semirigid endoscope with an external diameter of 0.95 mm was 
used for viewing and a 1.1-mm endoscope with a working channel to pass the 
guidewire (Laduscope®; Polydiagnost, Pfaffenhofen, Germany). The localization 
procedure allowed precise excision of the visualized target. The wire was retrieved 
through a periareolar incision and the targeted duct dissection commenced at the 
base of the nipple, following the duct proximally to the position of the rhomboid, 
excising the duct system beyond the identified lesion. If no lesion was identified, a 
lacrimal probe was used to cannulate the fluid-yielding duct and standard surgery 
performed to excise the offending duct system to a depth deemed appropriate by the 
operating surgeon (Fig. 1). 
Patients randomized to no duct endoscopy proceeded directly to standard 
surgery. The lacrimal probe cannulation and excision method described for the duct 
endoscopy group was used when no lesion was identified. Patients aged over 40 
years requiring major duct excision had a disc of subareolar tissue resected in 
addition to the offending duct cannulated by the lacrimal probe; the size of the disc 
and depth of the duct were determined by the operating surgeon.  
Resected specimens were orientated by marking sutures for pathological 
assessment. In all patients, the defect created by open surgery was approximated to 
enable repair with direct apposition of adjacent parenchymal tissue using absorbable 
sutures, avoiding any space for haematoma or seroma formation. The surgical 
incision was closed in layers with local anaesthetic infiltration comprising 20–40 ml of 
0.25 per cent chirocaine as preemptive analgesia before reversal of the general 
anaesthetic. 
 
Statistical analysis 
The histopathology findings after standard surgery for nipple discharge in the 
authors’ department showed a specific diagnosis to account for the nipple discharge 
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(such as papilloma or duct ectasia) in around 50 per cent of breasts. It was expected 
that duct endoscopy might increase the yield to 85 per cent. The study was designed 
to randomize 71 patients and on this basis to have over 83 per cent power based on 
a two-sided 5 per cent   significance level for the primary outcome.  
The primary endpoint was the sensitivity of successful visualization by duct 
endoscopy, aimed at 80 per cent in the duct endoscopy group; conversely, the 
procedure would be considered unsuccessful if the rate of visualization of a lesion fell 
to below 60 per cent. Based on this level of successful visualization, with 80 per cent 
power and one-sided 5 per cent  , 33 breasts were to be examined using duct 
endoscopy.  
Test characteristics of duct endoscopy in identifying any lesion were 
expressed as sensitivity, specificity, PPV and NPV in comparison with findings at 
pathology. Volume of the surgical resection specimen in the two groups was 
described using median (i.q.r.) and assessed for significant differences using the 
Mann–Whitney U test. The  2 test was used to compare histological findings 
between the groups.  Stata® version 13 (StataCorp, College Station, Texas, USA) 
was used for statistical analysis.   
Results 
Of 78 patients assessed for eligibility, seven decided not to participate in the study; 
the remaining 71 patients were randomized, accounting for 73 breasts with nipple 
discharge. Four women were withdrawn from from the study, either because of 
cancellation of the surgical procedure (2) or equipment failure (2). Complete analyses 
included 66 patients and 68 breasts for study, 31 breasts in the duct endoscopy 
group and 37 in the no-endoscopy group (Fig. 2). The median age overall was 49 
(range 19–81, i.q.r. 44–60) years, 49 (i.q.r. 44–60) years in the duct endoscopy group 
and 51 (46–58) years in the no-endoscopy group. Median follow-up in the two groups 
was 5.4 (i.q.r. 3.3–8.9) and 5.7 (3.1–9.0) years respectively.  
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Overall, there was only one complication: a haematoma in the no-endoscopy 
group that needed surgical evacuation. There were no wound infections in either 
group after surgery. No toxicities or serious adverse events were recorded. 
 
Outcome of duct endoscopy 
Of the 32 duct endoscopies performed, a single duct as the only fluid-yielding duct 
was examined in 22 breasts, two ducts in eight breasts, and more than three ducts 
were examined in two breasts. The index lesion was identified at a median distance 
of 2.5 (range 1–6) cm from the nipple surface. The median depth of inspection of all 
ducts studied was 5.5 (range 1–10) cm. Details of the number and order of ducts 
studied are shown in Table 1. 
Duct endoscopy (32 breasts) identified any lesion with a sensitivity of 12 of 15 
(80 (95 per cent c.i. 52 to 96) per cent), specificity of 12 of 17 (71 (44 to 90) per cent), 
PPV of 12 of 17 (71 (44 to 90) per cent) and NPV of 12 of 15 (80 (c.i. 52 to 96) per 
cent. Data on histopathology were missing for one patient in the duct endoscopy 
group and further analyses with regard to specific lesions identified were therefore 
based on 31 patients. The most common benign lesions identified were papilloma 
and duct ectasia; these specific entities were identified with overall accuracy of 90 
and 65 per cent respectively (Tables 2 and 3). Three patients had papillomas with 
atypia, two in the duct endoscopy group; both papillomas were identified by 
endoscopy and the atypical features of one were predicted by the presence of 
stranding.  
Adjunctive duct endoscopy, however, did not contribute to an increase in the 
correct histological yield to account for the nipple discharge between the two 
randomized groups (any lesion, P = 0.213; papilloma, P = 0.435; duct ectasia, P = 
0.806) (Table 4). 
Five patients were identified with ductal carcinoma in situ (DCIS), three in the 
duct endoscopy group and two in the no-endoscopy group. Duct endoscopy 
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successfully identified the DCIS as a flat lesion in two of three patients. The five 
DCIS cases comprised three of low grade and two of intermediate grade. None 
required adjuvant radiotherapy. One patient needed no further treatment whereas the 
other four required further surgery because of involved or close excision margins. 
Two patients had a wider excision and two a mastectomy. The latter patients 
included one woman in the no-endoscopy group who had low- and intermediate-
grade DCIS extending to 45 mm, and one in the duct endoscopy group diagnosed 
with intermediate-grade DCIS larger than 50 mm and a 10-mm grade 2 invasive 
breast cancer.  None of the patients with DCIS or invasive cancer had developed 
recurrence or progressed with any further malignant diagnosis at the time of census. 
The numbers of DCIS and breast cancer events were too small to evaluate test 
characteristic values for accuracy of duct endoscopy in identifying a malignant cause 
or predicting the extent of such disease.  
The median volume of the surgical resection specimen in the duct endoscopy 
group was 4875 (i.q.r. 2016–8280) mm3 compared with 4455 (2400–7000) mm3 in 
the no-endoscopy group (P = 0.577).  
 
Follow-up 
Two patients subsequently developed ipsilateral nipple discharge on follow-up, both 
in the duct endoscopy group. One was a single episode that resolved with no 
treatment; the second patient developed a new papillary lesion that was excised by 
vacuum excision biopsy as an interventional radiological procedure with no further 
recurrence of symptoms. Another patient in the duct endoscopy group developed 
contralateral nipple discharge during follow-up. No ipsilateral breast cancers formed 
in the follow-up period, but one contralateral cancer was diagnosed in a patient who 
had not undergone ductal endoscopy. 
 
Discussion  
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In this randomized trial of pathological nipple discharge, duct endoscopy was 
successful in the identification and localization of the causative lesion with high 
sensitivity, specificity, PPV and NPV. Duct endoscopy additionally offers the potential 
advantage of localization of unexpected deeper lesions within the breast. Duct 
endoscopy was found to be safe; no significant complications or adverse effects were 
observed.  
Benign papillomas were the commonest identifiable source of nipple 
discharge by direct view. Duct endoscopy was very accurate in diagnosing the 
presence of a papilloma, with a PPV and NPV of at least 90 per cent. Duct ectasia 
can be a gradation of dilatation and, unless the ducts are particularly tortuous, this 
finding may by under-reported by duct endoscopy as the duct under investigation is 
distended with saline infused through the working channel during the endoscopic 
procedure. Although duct endoscopy accurately recognized duct ectasia in this study 
(PPV 100 per cent), the NPV was only 52 per cent.  
  There were only three instances of atypia by histopathological criteria in the 
entire study cohort of 68 breasts, a finding compatible with reports in the current 
literature13. The rate of DCIS was similar in both groups and the yield of a malignant 
or atypical diagnosis was not increased by duct endoscopy. Duct endoscopy 
identified two of three instances of DCIS, but was not predictive of disease extent. 
The relatively low rate of DCIS and atypia observed may be explained by the strict 
inclusion criteria.  
Duct endoscopy is a costly and skilled procedure with a learning curve, which 
in most countries remains unfunded or not reimbursed. Consideration needs to be 
given to how the results of the present RCT can be used in the context of intraductal 
approaches generally and the future of duct endoscopy specifically.  
Early work focused on developing predictive and prognostic factors for breast 
cancer by assessing the internal milieu of the breast, and the breast duct fluid in 
direct contact with breast epithelial cells. Abnormal cells in duct fluid are a predictive 
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factor for future breast cancer risk20,21, and repeated access to breast duct fluid is 
feasible with high compliance, especially in populations at risk, such as BRCA1/2 
gene carriers or women attending family history clinics22,23. The limited cellularity of 
nipple aspirate cytology fluid can be overcome by ductal lavage24,25, but the 
reproducibility of cellular atypia on repeated sampling and subsequent correlation 
with pathology of the excised specimen can be variable26,27. Cellular and molecular 
techniques have identified cell products such as carbohydrates and proteins, along 
with a range of epigenetic and metabolomic markers from methylation and detailed 
quantitative PCR28–33, as potential markers. However, despite refining these methods 
to account for small volumes of pure duct fluid, or the effects of dilution from lavage, 
there remains no single marker, or panel of markers, that can be used as a reliable 
predictive or prognostic breast cancer biomarker. 
The fibre-optic technology underpinning microendoscopy is well established34. 
Most endoscopes have a light channel, an irrigation channel and a working channel 
through which microinstrumentation can be passed. Developments in 
microinstruments include forceps to biopsy, snares to extract papillomas and laser 
technology to treat target lesions. Successful interventional duct endoscopy has been 
reported in selected case series from enthusiastic centres16–19. Although the present 
study has shown no additional benefit in the adjunctive use of duct endoscopy to 
evaluate patients with persistent nipple discharge at the time of standard surgery, the 
trial results have demonstrated that duct endoscopy is a reliable means of identifying 
papillomas. Interventional duct endoscopy targeting resection through the endoscope 
is thus a reasonable next step in technological advancement. It remains unknown 
whether nipple discharge symptoms will relapse if the papilloma alone is treated, but 
not the duct. The fact that pathological nipple discharge is an essentially benign 
condition that can be treated as a simple surgical day case has to be weighed 
against the health economics of high-technology intervention if endoscopic 
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management of treating papillomas is to progress. The ability to offer therapy by 
intraductal means remains a theoretical goal35. 
 The present study has shown that duct endoscopy is accurate in identifying a 
target lesion causative of pathological nipple discharge, but does not improve the 
diagnostic yield compared with standard surgery. The future of duct endoscopy may 
lead to interventional approaches that avoid open surgery. Such intervention needs 
to be evaluated carefully and supported by evidence-based comparative studies of 
cost efficiency, particularly in the context of benign disease. 
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Figure Legends 
Fig. 1 Surgical procedure: a duct endoscope ex vivo showing wire and rhomboid that 
expands to fill the duct; b periareola surgical approach for microdochectomy or major 
duct excision; c surgical resection of wire-localized excision, with the proximal end of 
the wire emerging from the nipple end of the duct and the rhomboid within the 
specimen showing the distal duct containing the target lesion; and d surgical 
specimen following standard surgery with no localization wire 
 
Fig. 2 CONSORT flow diagram for the trial 
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Table 1 Technical information on duct endoscopic examination in the 32 breasts 
randomized to duct endoscopy 
 No. of breasts* 
No. of ducts cannulated  
   1  
   ≥ 2  
 
22 
10 
Deepest order of duct inspected  
First order 
Second order 
Third order 
Fourth order 
6 
14 
10 
2 
First-order ducts examined‡  
Second-order ducts examined 
   No. per breast† 
Third-order ducts examined 
   No. per breast† 
Fourth-order ducts examined 
   No. per breast† 
32 
27 
2 (2–4) 
17 
2 (2–3) 
7 
2 (2–3) 
Limit of inspection among all ducts 
examined (cm)†  
5.5 (1–10)  
*Unless indicated otherwise; †values are median (range). ‡In five women, the first-
order duct was the only accessible duct. 
 
 
 
Table 2 Identification of papilloma by duct endoscopy compared with 
histopathological findings in the duct endoscopy group 
 
Papilloma identified on 
histopathology  
Yes No Total 
Papilloma identified 
on duct endoscopy 
   
Yes 10 1 11 
No 2 18 20 
 
Total 12 19 31 
Sensitivity 
Specificity 
PPV 
NPV 
10 of 12 (83; 52, 98) 
18 of 19 (95; 74, 100) 
10 of 11 (91; 59, 100) 
18 of 20 (90; 68, 99) 
Values in parentheses are percentages with 95 per cent confidence intervals. PPV, 
positive predictive value; NPV, negative predictive value. 
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Table 3 Identification of duct ectasia by duct endoscopy compared with 
histopathological findings in the duct endoscopy group 
 
 Duct ectasia identified on 
histopathology 
Total Yes  No 
Duct ectasia 
identified on duct 
endoscopy 
   
Yes 8 0 8 
No 11 12 23 
 
Total 19 12 31 
 
Sensitivity 
Specificity 
PPV 
NPV 
8 of 19 (42; 20, 67) 
12 of 12 (100; 74, 100) 
8 of 8 (100 (63, 100) 
12 of 23 (52; 31, 73) 
Values in parentheses are percentages with 95 per cent confidence intervals. PPV, 
positive predictive value; NPV, negative predictive value. 
 
 
 
Table 4 Comparison of histological yield in the two groups 
 
Duct endoscopy 
(n = 32)  
No duct 
endoscopy 
(n = 37) P* 
Any lesion on histology   0.213 
Yes 15 11   
No 17 26   
Papilloma on histology   0.435 
Yes 12* 10   
No 19* 27   
Duct ectasia identified by 
duct endoscopy 
  0.806 
Yes 20  21   
No 12  16   
*Data missing for one patient in the duct endoscopy group. †Fisher’s exact test. 
 
a Duct endoscope b Periareola surgical approach
c Surgical excision of lesion d Surgical specimen
Figure 1
  Assessed for eligibility 
n =78 patients 
Randomized  
n =71 patients 
 (73 breasts) 
Excluded n =7 patients 
(Requested off study endoscopy 
n = 7) 
 
Allocated to duct endoscopy n=35 
breasts (n=33 patients)  
• Received intervention n=32 
breasts (n=30 patients) 
• Did not receive intervention 
n=3 breasts (3 patients) 
o equipment failure n=2 
o surgery cancelled n=1      
Allocated to standard 
microdochectomy n=38 (patients 
and breasts) 
• Received intervention 
n=37breasts (n=37 patients) 
• Did not receive intervention 
n=1breast(surgery 
cancelled)(n=1 patient) 
Lost to follow-up n=0 
Discontinued intervention n=0 
Unable to retrieve information 
n=1breast (n=1 patient) 
 
Lost to follow-up n=0 
Discontinued intervention  n=0 
Analysed n=31(n=29 patients) 
Excluded from analysis n=0  
Analysed n=37 (breasts and patients) 
Excluded from analysis n=0 
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Figure 2 
